Health Condition 1: null- Patients with resectable Carcinoma Gastroesophageal junction without clinical metastasis
Conditions
Interventions
Intervention1: DCF ( Docetaxel
5- Flurouracil) based chemotherapy regimen: 3 cycles of DCF ( Docetaxel
5- Flurouracil) based chemotherapy regimen before surgery and 3 more cycles in adjuvant setting. surgery will be performed after 6 weeks from first 3 cycles.Common Terminology criteria for Adverse eve
5-Flurouracil weekly with Radiotherapy (50.4 Gy in 28 fraction): Chemotherapy will constitute cisplatin
5-Flurouracil weekly concurrently with with Radiotherapy (50.4 Gy in 28 fractions) followed by surgery after 6 weeks. Common Terminology criteria for Adverse events (CTCAE) will be used to measure tox
Sponsors
Dr Shivendra Singh
Eligibility
Inclusion criteria
Inclusion criteria: All patients with resectable and hitologically proven adenocarcinoma of Gastroesophageal junction(type I,II,III) who are fit for surgery(ECOG performance status 0,1,2); No Distant metastasis on PET scan and Staging Laparoscopy
Exclusion criteria
Exclusion criteria: Distant metastasis on Staging Laparoscopy or on PET scan; refusal for informed consent for procedure; locally unresectable tumors; tumors falling in stage cT1N0 on Endoscopic ultrasound examination
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of median survival rates in patient treated with NACT followed by surgery with NACTRT followed by surgeryTimepoint: 30 days from surgery ; 3 month; 6 month; 1 year; 3 years ; 5 years | — |
Secondary
| Measure | Time frame |
|---|---|
| Pathological response; Progression free survival; number of R0 resections; treatment toxicity; quality of lifeTimepoint: 30 days from surgery ; 3 month; 6 month; 1 year; 3 years ; 5 years | — |
Countries
India
Contacts
Public ContactDr Shivendra Singh
Rajiv Gandhi Cancer Research Institute; Rohini; Sector 5; Delhi 110085 North West DELHI 110085
Outcome results
None listed